Protara Therapeutics, Inc. (TARA) Stock Price & Analysis
Protara Therapeutics, Inc. (TARA) closed at USD 2.44 on Thursday, October 22, 2026, down 2.40% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 2.5; the Oct 22, 2026 session ranged USD 2.42–2.53 on volume of 1,761,523 shares. Market capitalization is $144.19M, with a 52-week range of USD 2.3–7.82 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TARA.md
Key facts (TARA)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 25.71 (range 20–30).
- Total return with dividends: 1Y -52.7% vs S&P 500 +14.9%; 5Y -63.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD -0.36, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TARA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$47.5M | -$67.1M | -$43.6M | -$49.2M | -$64.5M | -$76.8M |
| Net income | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M | -$70.0M |
| EPS (diluted) | -$4.21 | -$5.86 | -$3.57 | -$2.17 | -$1.34 | — |
| Free cash flow | -$35.1M | -$26.6M | -$37.6M | -$35.9M | -$56.5M | — |
| Cash + short-term investments | $91.2M | $84.4M | $65.6M | $170M | $156M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TARA)
P/B 0.9x · Earnings yield -48.56%
Analysts (TARA)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 25.71 (low 20, high 30).
Total return (dividends reinvested) (TARA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -52.7% | -63.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -52.8% | -18.3% |
| Volatility (annualized) | 74.5% | 75.2% |
| Max drawdown | -69.3% (Nov 2025→Oct 2026) | -84.3% (Nov 2021→Nov 2023) |
TARA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.36 | $-0.33 | +9.7% | $0 | 6 |
| Next quarter (ends Dec 2026) | $-0.38 | $-0.34 | +9.5% | $0 | 6 |
| Current fiscal year (ends Dec 2026) | $-1.39 | $-1.39 | +0.4% | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-1.69 | $-1.64 | +2.9% | $1.0M | 7 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 2.44 |
|---|---|
| Change | ▼ 2.40% (down) |
| Previous Close | USD 2.5 |
| Open | USD 2.47 |
| Day Range | USD 2.42 – 2.53 |
| 52-Week Range | USD 2.3 – 7.82 |
| Volume | 1,761,523 shares |
| Market Cap | $144.19M |
| Exchange | NGM |
Technical Analysis (TARA)
Nexqual's technical model rates TARA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 30.84 (neutral) |
| vs SMA50 | Below (USD 3.37) |
| MACD | -0.28 (negative) |
Analyst Ratings (TARA)
Wall Street analysts rate TARA "Buy" based on 8 analysts, with a mean price target of USD 25.71 (range USD 20–30), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 25.71 |
| High Target | USD 30 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (TARA)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.31 ▼ miss |
| 2026-03-31 | USD -0.31 vs est -0.37 ▲ beat |
| 2025-12-31 | USD -0.38 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.39 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (TARA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -45.80% |
| Debt / Equity | 0.02 |
| Current Ratio | 10.97 |
| Total Cash | $142.49M |
| Total Debt | $2.75M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (TARA)
Nexqual rates Protara Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $142M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$56M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -46%, ROA -28.8% |
Ownership (TARA)
| Insider Ownership | +2.30% |
|---|---|
| Institutional Ownership | +78.29% |
| Shares Outstanding | 59.10M |
| Float | 54.88M |
| Short % of Float | +9.96% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (TARA)
Protara Therapeutics, Inc. is led by Jesse Shefferman, Co-founder, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| Co-founder, CEO, President & Director | Jesse Shefferman |
|---|---|
| Chief Financial Officer | Patrick Fabbio |
| Senior Vice President of Investor Relations & Corporate Affairs | Justine O'Malley |
| Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist | Carla Beckham |
| Medical Director of START Carolinas/ Carolina Urologic Research Center | Neal D. Shore F.A.C.S. |
Major Backers & Investors (TARA)
Notable institutional backers of Protara Therapeutics, Inc. include Jupiter Topco LLC, Millennium Management, Velan Capital Investment Management LP, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 7.95% |
| Millennium Management | 5.25% |
| Velan Capital Investment Management LP | 4.81% |
| Blackstone Inc | 3.83% |
| Orbimed Advisors LLC. | 3.76% |
| Sio Capital Management, LLC | 3.25% |
| Acorn Capital Advisors, LLC | 2.96% |
| Integral Health Asset Management, LLC | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.2% |
| Vanguard Group | 3.89% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt